甲氨蝶呤通过激活IFN-γR/STAT1通路抑制糖皮质激素诱导的破骨细胞生成治疗类风湿关节炎
研究利用糖皮质激素诱导骨质疏松小鼠模型和脂多糖诱导关节炎小鼠模型,探讨甲氨蝶呤联合糖皮质激素治疗类风湿关节炎的机制。结果显示糖皮质激素而非甲氨蝶呤快速抑制滑膜炎,甲氨蝶呤通过增强A2AR与IFN-γR相互作用激活IFN-γR/STAT1通路,抑制糖皮质激素诱导的破骨细胞生成并减轻骨丢失。
要点
- 糖皮质激素而非甲氨蝶呤快速抑制关节炎模型中的滑膜炎。
- 甲氨蝶呤抑制糖皮质激素诱导的破骨细胞生成并减轻糖皮质激素诱导骨质疏松的骨丢失。
- 甲氨蝶呤通过增强A2AR与IFN-γR相互作用激活IFN-γR/STAT1通路,减少mGR与STAT1的相互作用。
核心结论
- 甲氨蝶呤可使糖皮质激素有效抑制滑膜炎并减少糖皮质激素诱导的骨丢失。
研究设计与样本
- 使用糖皮质激素诱导骨质疏松小鼠模型研究甲氨蝶呤的骨保护作用。
- 使用脂多糖诱导关节炎小鼠模型评估糖皮质激素和甲氨蝶呤的抗炎作用。
- 通过TRAP染色和微型计算机断层扫描评估甲氨蝶呤对破骨细胞生成的功能作用。
- 采用蛋白质印迹、RT-qPCR和免疫共沉淀探讨潜在机制。
主要发现
- 糖皮质激素而非甲氨蝶呤在关节炎模型中快速抑制滑膜炎。
- 甲氨蝶呤在体外抑制糖皮质激素诱导的破骨细胞生成,并减轻糖皮质激素诱导骨质疏松所致的骨丢失。
- 糖皮质激素增强膜糖皮质激素受体(mGR)与信号转导和转录激活因子1(STAT1)的相互作用,抑制IFN-γR/STAT1信号通路。
- 甲氨蝶呤通过增强A2AR与IFN-γR的相互作用激活IFN-γR/STAT1信号级联,减少mGR与STAT1的相互作用,从而抑制糖皮质激素诱导的破骨细胞生成。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by the synovitis and bone erosion. The combination therapy of glucocorticoids (GCs) and methotrexate (MTX) is recommended in early RA management, although the precise underlying mechanism of action remains unclear. This study is aimed to clarify the mechanism of MTX in combined with GC in treating RA. METHODS: GC-induced osteoporosis (GIOP) mouse model was used to investigate the bone-protective role of MTX. Lipopolysaccharide-induced arthritis mouse model was used to evaluate the anti-inflammatory effects of GCs and MTX. Functional role of MTX on osteoclastogenesis was assessed by trap staining and micro-computer tomography. Western blot, RT-qPCR and coimmunoprecipitation were used to explore the underlying mechanisms. RESULTS: We demonstrate that GCs, but not MTX, rapidly inhibited synovitis in arthritis model. MTX treatment was observed to inhibit osteoclastogenesis induced by GC in vitro and mitigate bone loss attributed by GIOP. GCs were found to augment the interaction between the membrane GC receptor (mGR) and signal transducer and activator of transcription 1 (STAT1), leading to the suppression of IFN-γR/STAT1 signalling pathways. Interestingly, MTX was found to inhibit osteoclastogenesis induced by GCs through the enhancement of the A2AR and IFN-γR interaction, thereby activating the IFN-γR/STAT1 signalling cascade. Consequently, this process results in a reduction in the mGR and STAT1 interaction. CONCLUSIONS: Our study provides compelling evidence that MTX can make GCs effectively to suppress synovitis and reduce bone loss induced by GCs. This sheds light on the potential mechanistic insights underlying the efficacy of GCs in conjunction with MTX for treating RA.
引用
- Teng Y, Yin H, Feng R, et al. Methotrexate inhibits glucocorticoids-induced osteoclastogenesis via activating IFN-γR/STAT1 pathway in the treatment of rheumatoid arthritis. RMD Open. 2024. PMID: 39510764. doi:10.1136/rmdopen-2024-004886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。